Enzone
Links shared publicly online about this topic
Enzon stops study of colorectal cancer treatment - CNBC
cnbc.com — “Enzon Pharmaceuticals Inc. will halt clinical work on a potential metastatic colorectal cancer treatment, the company said Thursday, to focus on treatments with "nearer-term commercial potential."” View full resource at cnbc.com
Most Recently Shared on May 20, 2011 at 3:00 pm By:
Raymond DuBois Physician, Doctor, Internist, Gastroenterologist, and Health Executive
Enzon stops study of #colorectal #cancer treatment: http://www.cnbc.com/id/43099307
Enzon Opens Pediatric Study Of PEG-SN38
medicalnewstoday.com — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylat” View full resource at medicalnewstoday.com
Most Recently Shared on February 26, 2010 at 4:06 pm By:
Enzon Opens Pediatric Study Of PEG-SN38 http://mnt.to/3y9z #cancer
UPDATE 1-Enzon Pharma to cut workforce by 26 pct, take charges | Reuters
reuters.com — “* Expects $2.8-$3 mln related charges * Says charges mostly to represent cash expenditure Dec 7 (Reuters) - Enzon Pharmaceuticals Inc said it will cut 33 positions as part of its efforts” View full resource at reuters.com
Most Recently Shared on December 7, 2010 at 12:14 pm By:
John Carroll Health Communicator
Enzon is cutting 33 jobs. http://reut.rs/eEbwvu
Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting - Drugs.com MedNews
drugs.com — “Third-Generation mRNA-Targeting Compounds Show Potent Anti-Tumor Activity Nov 17, 2010 - Enzon Pharmaceuticals, Inc. (Nasdaq ENZN) today presented data from pre” View full resource at drugs.com
Most Recently Shared on November 17, 2010 at 4:46 pm By:
Drugs and Devices OW OW Health
Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting: Third-Generation mRNA-Targeting Compounds Show Potent ... http://bit.ly/cakf0M #drug
Enzon 1Q Profit Plunges on Loss of Revenue - Drugs.com MedNews
drugs.com — “From Associated Press (May 6, 2011) Enzon Pharmaceuticals Inc. said Friday that its first-quarter profit plunged on a loss of revenue following the sale of the” View full resource at drugs.com
Most Recently Shared on May 6, 2011 at 4:08 pm By:
Drugs and Devices OW OW Health
Enzon 1Q Profit Plunges on Loss of Revenue: From Associated Press (May 6, 2011) BRIDGEWATER, N.J. -- Enzon... http://bit.ly/mRy41v #drug
Enzon To Begin Phase 1 Study Of Novel Androgen Receptor MRNA Antagonist In Castration-Resistant Prostate Cancer
medicalnewstoday.com — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b stu” View full resource at medicalnewstoday.com
Most Recently Shared on January 12, 2011 at 11:37 am By:
Enzon To Begin Phase 1 Study Of Novel Androgen Receptor MRNA Antagonist In Castration-Resistant Prostate Cancer Enzon P.. http://dld.bz/FuY5
Enzon Announces Publication Of Preclinical Study Data Of PEG-SN38 In Pediatric Neuroblastoma
medicalnewstoday.com — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to” View full resource at medicalnewstoday.com
Most Recently Shared on October 7, 2010 at 3:05 pm By:
MNT Pediatrics News Pediatrics and Health News
Enzon Announces Publication Of Preclinical Study Data Of PEG-SN38 In Pediatric Neuroblastoma http://mnt.to/3KS3 #pediatrics
Enzon Announces Discontinuation Of PEG-SN38 Program In Metastatic Colorectal Carcinoma In Light Of Evolving Standards Of Care
medicalnewstoday.com — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its P” View full resource at medicalnewstoday.com
Most Recently Shared on May 20, 2011 at 11:05 am By:
Enzon Announces Discontinuation Of PEG-SN38 Program In Metastatic Colorectal Carcinoma In Light Of Evolving Standards ... http://mnt.to/3W8Q
Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million
news-medical.net — “Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.” View full resource at news-medical.net
Most Recently Shared on May 7, 2011 at 5:32 am By:
Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million: Enzon Pharmaceuticals, I... http://bit.ly/lm7jpl
Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program
news-medical.net — “Enzon Pharmaceuticals, Inc. today announced that it has been awarded $1.2 million in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.” View full resource at news-medical.net
Most Recently Shared on November 3, 2010 at 6:15 am By:
Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program: Enzon Pharmaceu... http://bit.ly/9z1MGc
Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million
news-medical.net — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon's four marketed specialty pharmaceutical products through 2014.” View full resource at news-medical.net
Most Recently Shared on November 9, 2009 at 5:24 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Gro.. http://bit.ly/1szgh1
Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium
news-medical.net — “Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.” View full resource at news-medical.net
Most Recently Shared on October 30, 2010 at 10:20 am By:
Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium: Enzon Pharmaceuticals... http://bit.ly/9XG8gf
A Tale of 2 Drug CEOs: Sepracor's Succeeded, Enzon's Failed, Yet Both Are Showered With Cash | BNET Pharma Blog | BNET
industry.bnet.com — “Enzon (ENZN) CEO Jeffrey H. Buchalter and Sepracor CEO Adrian Adams both left their jobs in the last couple of days for very different reasons. But ev” View full resource at industry.bnet.com
Most Recently Shared on February 23, 2010 at 12:05 am By:
Jim Edwards Health Communicator
A Tale of 2 Drug CEOs: Sepracor's Succeeded, Enzon's Failed, Yet Both Are Showered With Cash: Enzon (ENZN) CEO Je... http://bit.ly/cu5BSR
Enzon Announces Discontinuation of PEG-SN38 Program in Metastatic Colorectal Carcinoma in Light of Evolving Standards of Care - Drugs.com MedNews
drugs.com — “PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer, Other Solid Tumors May 19, 2011 - Enzon Pharmaceuticals, Inc. (Nasdaq ENZN) today announced tha” View full resource at drugs.com
Most Recently Shared on May 19, 2011 at 1:07 pm By:
Drugs and Devices OW OW Health
Enzon Announces Discontinuation of PEG-SN38 Program in Metastatic Colorectal Carcinoma in Light of Evolvin... http://bit.ly/mqA52y #drug
Archimedes Pharma Raises GBP65 Mln For US Ops, Sales Push - WSJ.com
online.wsj.com — “Archimedes Pharma Raises GBP65 Mln For US Ops, Sales Push - WSJ.com” View full resource at online.wsj.com
Most Recently Shared on March 2, 2010 at 12:18 pm By:
John Carroll Health Communicator
The UK's Archimedes raises $100M and names Jeffrey Buchalter , former Enzon CEO, to top post. http://bit.ly/bcvKfG
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Raymond DuBois
Past President of AACR, Cancer Researcher and Provost/EVP of the MD Anderson Cancer Center in Houston
-
MNT Cancer News
The latest cancer news published daily. Articles from research centers, universities and prestigious journals.
-
John Carroll
John Carroll is editor of FierceBiotech, where he primarily covers drug development and has for the past eight years.
Advertisement
